Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus

Fabiana Rollini(Florida College), Dominick J. Angiolillo(University of Florida), Francesco Franchi(Florida College), M. Tariq Bhatti(Mayo Clinic), Theodore A. Bass(Society for Cardiovascular Angiography and Interventions), Zeina Alobaidi(University of Florida), Lydia R. Engwenyu, Jung Rae Cho(Hallym University Kangnam Sacred Heart Hospital), Elisabetta Ferrante(University of Florida), Martin Zenni(University of Florida), Christopher DeGroat(University of Florida), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom))
Thrombosis and Haemostasis
October 27, 2016
10.1160/th16-08-0594
Cited by 7

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
|New England Journal of Medicine|2013|825
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
|Circulation|2008|757
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
Platelet Inhibition with Cangrelor in Patients Undergoing PCI
|New England Journal of Medicine|2009|618